5 Results for "

synthetic macrocyclic peptides

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "synthetic macrocyclic peptides" in MCE Product Catalog:

Cat. No.: HY-149988
CAS No.: 3072696-60-4
Target:  

MDM-2/p53

Research Areas:  

Cancer

UNP-6457 is a potent active MDM2-p53 interaction inhibitor with an IC50 values of 8.9 nM .
loading...
    loading...
Cat. No.: HY-P11676
CAS No.: 1814918-91-6
Synonyms: BRII-693; QPX9003
Target:  

Antibiotic Bacterial

Research Areas:  

Infection

Soralimixin (BRII-693), a Polymyxin derivative, is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic. Soralimixin can be used for the study of infections caused by drug-resistant Gram-negative pathogens .
loading...
    loading...
Cat. No.: HY-P12216
CAS No.: 3115127-25-5
Target:  

Drug Intermediate

Research Areas:  

Metabolic Disease

Enlicitide northern fragment 4 is a key intermediate obtained via the retrosynthetic disconnection of Enlicitide decanoate (HY-W1126955). Enlicitide northern fragment 4 participates in the protecting-group-free biocatalytic convergent assembly of Enlicitide decanoate, an oral macrocyclic peptide PCSK9 inhibitor. Enlicitide northern fragment 4 can be used for the synthesis of Enlicitide decanoate, thereby supporting research related to hypercholesterolemia .
loading...
    loading...
Cat. No.: HY-L932V0
2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.

Cat. No.: HY-L932V
2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.